RDNT
BEARISH
$60.39
Live
RadNet, Inc. · NASDAQ
Target $92.38
(+53.0%)
$46.76
52W Range
$85.84
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 18, 2026
Market cap
$4.69B
P/E
N/A
ROE
1.4%
Profit margin
-0.9%
Debt/Equity
1.37
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
RDNT exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While revenue growth remains positive at 14.8%, the company is struggling with negative profit margins (-0.91%) and a catastrophic collapse in year-over-year EPS growth (-104.5%). There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling and negative earnings surprises. The valuation is aggressive, with a forward P/E of 58.82 that is not supported by current profitability.
Key Strengths
Consistent double-digit revenue growth (14.8% YoY)
Healthy short-term liquidity with a Current Ratio of 1.76
Strong long-term price appreciation (171.5% over 5 years)
Positive operating margin (6.83%) despite negative net profit
Strong analyst backing with a target price of $92.38
Key Risks
Critical financial health failure (Piotroski F-Score 2/9)
Severe earnings deterioration (-104.5% YoY EPS growth)
Negative net profit margins indicating inability to convert revenue to bottom-line profit
Bearish insider sentiment with $5.4M in recent sales and zero buys
High valuation risk with a Forward P/E of 58.82
AI Fair Value Estimate
Based on comprehensive analysis
$48.5
-19.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
30
45
60
15
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 2/9, Negative Profit Margin, EPS Collapse, Insider Selling
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- PEG ratio of 0.96 suggests growth is priced in
Watchpoints
- Forward P/E of 58.82 is excessive
- Price/Book of 4.29 is high for the current ROE
Future
45/100
Ref Growth rates
Positives
- Revenue growth is steady at 14.8%
Watchpoints
- Earnings surprises are heavily negative (-24.56% avg)
- EPS growth is trending sharply downward
Past
60/100
Ref Historical trends
Positives
- Strong 3Y and 5Y price performance
Watchpoints
- Recent 6-month trend is bearish (-21.5%)
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio above 1.5
Watchpoints
- Piotroski F-Score of 2/9 is a critical warning sign
- Debt/Equity of 1.37 is moderate to high
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$60.39
Analyst Target
$92.38
Upside/Downside
+53.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RDNT and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RDNT
RadNet, Inc.
Primary
|
+171.5% | +117.6% | +21.3% | -21.5% | -2.6% | +8.9% |
|
ALKS
Alkermes plc
Peer
|
+40.1% | +3.5% | -17.4% | +2.9% | -20.5% | -3.0% |
|
FOLD
Amicus Therapeutics, Inc.
Peer
|
+55.8% | +30.6% | +110.0% | +75.0% | +0.8% | +0.2% |
|
OPCH
Option Care Health, Inc.
Peer
|
+46.4% | -9.8% | -12.2% | +4.5% | -3.6% | -2.8% |
|
MMSI
Merit Medical Systems, Inc.
Peer
|
+15.0% | -8.9% | -24.4% | -12.4% | +2.0% | +4.7% |
RDN
RadNet, Inc.
Primary
5Y
+171.5%
3Y
+117.6%
1Y
+21.3%
6M
-21.5%
1M
-2.6%
1W
+8.9%
ALK
Alkermes plc
Peer
5Y
+40.1%
3Y
+3.5%
1Y
-17.4%
6M
+2.9%
1M
-20.5%
1W
-3.0%
FOL
Amicus Therapeutics, Inc.
Peer
5Y
+55.8%
3Y
+30.6%
1Y
+110.0%
6M
+75.0%
1M
+0.8%
1W
+0.2%
OPC
Option Care Health, Inc.
Peer
5Y
+46.4%
3Y
-9.8%
1Y
-12.2%
6M
+4.5%
1M
-3.6%
1W
-2.8%
MMS
Merit Medical Systems, Inc.
Peer
5Y
+15.0%
3Y
-8.9%
1Y
-24.4%
6M
-12.4%
1M
+2.0%
1W
+4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
58.82
PEG Ratio
0.96
P/B Ratio
4.29
P/S Ratio
2.3
EV/Revenue
2.96
EV/EBITDA
24.88
Market Cap
$4.69B
Profitability
Profit margins and return metrics
Profit Margin
-0.91%
Operating Margin
6.83%
Gross Margin
18.17%
ROE
1.37%
ROA
1.61%
Growth
Revenue and earnings growth rates
Revenue Growth
+14.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+14.8%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.37
Moderate
Current Ratio
1.76
Good
Quick Ratio
1.67
Excellent
Cash/Share
$9.88
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
13.9%
Op. Margin
6.4%
Net Margin
-0.1%
Total Assets
$3.8B
Liabilities
$2.4B
Equity
$1.1B
Debt/Equity
2.20x
Operating CF
$0.1B
CapEx
$-0.1B
Free Cash Flow
$0.0B
FCF Yield
39%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-02
$-0.01
-106.6% surprise
2025-11-09
$0.07
-65.0% surprise
2025-08-10
$0.31
+97.9% surprise
Healthcare Sector Comparison
Comparing RDNT against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
1.37%
This Stock
vs
-100.15%
Sector Avg
-101.4%
(Below Avg)
Profit Margin
-0.91%
This Stock
vs
-13.63%
Sector Avg
-93.3%
(Weaker)
Debt to Equity
1.37
This Stock
vs
3.22
Sector Avg
-57.4%
(Less Debt)
Revenue Growth
14.8%
This Stock
vs
121.05%
Sector Avg
-87.8%
(Slower)
Current Ratio
1.76
This Stock
vs
4.55
Sector Avg
-61.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RDNT
RadNet, Inc.
|
BEARISH | $4.69B | - | 1.4% | -0.9% | $60.39 | |
|
ALKS
Alkermes plc
|
BEARISH | $4.63B | 19.41 | 14.7% | 16.4% | $27.76 | Compare |
|
FOLD
Amicus Therapeutics, Inc.
|
BEARISH | $4.54B | - | -11.6% | -4.3% | $14.47 | Compare |
|
OPCH
Option Care Health, Inc.
|
NEUTRAL | $4.45B | 22.32 | 15.2% | 3.7% | $28.34 | Compare |
|
MMSI
Merit Medical Systems, Inc.
|
NEUTRAL | $4.21B | 33.12 | 8.7% | 8.5% | $70.54 | Compare |
RDNT
RadNet, Inc.
BEARISH
Mkt Cap
$4.7B
P/E
-
ROE
1.4%
Price
$60.39
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | SORENSEN ALMA GREGORY | Officer and Director | Gift | 7,000 | - |
| 2026-03-19 | SORENSEN ALMA GREGORY | Officer and Director | Sale | 15,000 | $933,014 |
| 2026-03-18 | SORENSEN ALMA GREGORY | Officer and Director | Sale | 15,000 | $932,280 |
| 2026-03-10 | SORENSEN ALMA GREGORY | Officer and Director | Stock Award | 62,964 | - |
| 2026-03-03 | MURDOCK MICHAEL N | Officer | Stock Award | 6,613 | - |
| 2026-03-03 | HAMES NORMAN R | Officer | Stock Award | 25,145 | - |
| 2026-03-03 | BERGER HOWARD G FRAN | Chief Executive Officer | Stock Award | 124,001 | - |
| 2026-03-03 | STOLPER MARK D | Chief Financial Officer | Stock Award | 18,228 | - |
| 2026-03-03 | FORTHUBER STEPHEN M | President | Stock Award | 22,045 | - |
| 2026-03-03 | PATEL MITAL | Officer | Stock Award | 20,667 | - |
| 2026-03-03 | SORENSEN ALMA GREGORY | Officer and Director | Stock Award | 16,533 | - |
| 2026-03-03 | KATZ DAVID JEFFREY | Officer | Stock Award | 19,289 | - |
| 2026-03-03 | WESDORP CORNELIS | President | Stock Award | 20,330 | - |
| 2025-12-10 | STOLPER MARK D | Chief Financial Officer | Option Exercise | 35,703 | $216,717 |
| 2025-12-10 | KATZ DAVID JEFFREY | Officer | Option Exercise | 3,396 | $99,978 |
SORENSEN ALMA GREGORY
Officer and Director
2026-03-19
7,000 shares
SORENSEN ALMA GREGORY
Officer and Director
2026-03-19
15,000 shares
·
$933,014
SORENSEN ALMA GREGORY
Officer and Director
2026-03-18
15,000 shares
·
$932,280
SORENSEN ALMA GREGORY
Officer and Director
2026-03-10
62,964 shares
MURDOCK MICHAEL N
Officer
2026-03-03
6,613 shares
HAMES NORMAN R
Officer
2026-03-03
25,145 shares
BERGER HOWARD G FRAN
Chief Executive Officer
2026-03-03
124,001 shares
STOLPER MARK D
Chief Financial Officer
2026-03-03
18,228 shares
FORTHUBER STEPHEN M
President
2026-03-03
22,045 shares
PATEL MITAL
Officer
2026-03-03
20,667 shares
SORENSEN ALMA GREGORY
Officer and Director
2026-03-03
16,533 shares
KATZ DAVID JEFFREY
Officer
2026-03-03
19,289 shares
WESDORP CORNELIS
President
2026-03-03
20,330 shares
STOLPER MARK D
Chief Financial Officer
2025-12-10
35,703 shares
·
$216,717
KATZ DAVID JEFFREY
Officer
2025-12-10
3,396 shares
·
$99,978
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
10-K
8-K
8-K
10-Q
8-K
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
8 analysts
Keybanc
2026-01-09
Overweight
B. Riley Securities
2025-12-01
Buy
Buy
Barclays
2025-11-13
Overweight
Overweight
Truist Securities
2025-11-12
Buy
Buy
Past News Coverage
Recent headlines mentioning RDNT from our newsroom.
Newest → oldest
No matching news yet.